1887

Abstract

The purpose of this work was to assess the ability of plasmid DNA encoding hepatitis B virus (HBV) HBsAg encapsulated in poly(-lactide-co-glycolic acid) (PLGA) microparticles to induce local and systemic HBsAg-specific immunity following a single dose of oral immunization. RT-PCR analysis demonstrated prolonged transcription of plasmid DNA, consistent with the sustained expression and presentation of target antigen observed by confocal laser scanning microscopy, in gut-associated lymphocyte tissue (GALT) from mice immunized orally with plasmid DNA encapsulated into PLGA microparticles. Oral administration of PLGA-DNA microparticles induced a long-lasting and stable antigen-specific antibody response, both serum total antibody and intestinal IgA, in BALB/c mice. Mice immunized orally exhibited antigen-specific gamma interferon production and cytotoxic T lymphocyte responses in spleen and GALT after restimulation with HBsAg or tumour cells stably expressing HBsAg. In contrast, naked DNA vaccines given by intramuscular injection induced only systemic cellular and humoral responses to HBsAg, which were much lower than the responses elicited by oral DNA encapsulated in PLGA microparticles at equivalent doses. The results are encouraging with regard to obtaining good compliance and vaccination coverage with candidate plasmid DNA vaccines, especially in developing countries.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80575-0
2005-03-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/3/vir860601.html?itemId=/content/journal/jgv/10.1099/vir.0.80575-0&mimeType=html&fmt=ahah

References

  1. Baras B., Benoit M. A., Dupre L., Poulain-Godefroy O., Schacht A. M., Capron A., Gillard J., Riveau G. 1999; Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect Immun 67:2643–2648
    [Google Scholar]
  2. Boyer J. D., Cohen A. D., Vogt S. 11 other authors 2000; Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 181:476–483 [CrossRef]
    [Google Scholar]
  3. Brazolot Millan C. L., Weeratna R., Krieg A. M., Siegrist C. A., Davis H. L. 1998; CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95:15553–15558 [CrossRef]
    [Google Scholar]
  4. Davis H. L., McCluskie M. J., Gerin J. L., Purcell R. H. 1996; DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A 93:7213–7218 [CrossRef]
    [Google Scholar]
  5. Garulli B., Kawaoka Y., Castrucci M. R. 2004; Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol 78:1020–1025 [CrossRef]
    [Google Scholar]
  6. Hedley M. L. 2003; Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin Biol Ther 3:903–910 [CrossRef]
    [Google Scholar]
  7. Herrmann J. E., Chen S. C., Jones D. H., Tinsley-Bown A., Fynan E. F., Greenberg H. B., Farrar G. H. 1999; Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259:148–153 [CrossRef]
    [Google Scholar]
  8. Illum L., Church A. E., Butterworth M. D., Arien A., Whetstone J., Davis S. S. 2001; Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm Res 18:640–645 [CrossRef]
    [Google Scholar]
  9. Kaneko H., Bednarek I., Wierzbicki A., Kiszka I., Dmochowski M., Wasik T. J., Kaneko Y., Kozbor D. 2000; Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267:8–16 [CrossRef]
    [Google Scholar]
  10. Kim S. Y., Doh H. J., Ahn J. S., Ha Y. J., Jang M. H., Chung S. I., Park H. J. 1999; Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(d,l-lactide-co-glycolide) microparticles. Vaccine 17:607–616 [CrossRef]
    [Google Scholar]
  11. Klencke B., Matijevic M., Urban R. G. 10 other authors 2002; Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8:1028–1037
    [Google Scholar]
  12. Kura M. M., Hira S., Kohli M., Dalal P. J., Ramnani V. K., Jagtap M. R. 1998; High occurrence of HBV among STD clinic attenders in Bombay, India. Int J STD AIDS 9:231–233 [CrossRef]
    [Google Scholar]
  13. Kutteh W. H., Kantele A., Moldoveanu Z., Crowley-Nowick P. A., Mestecky J. 2001; Induction of specific immune responses in the genital tract of women after oral or rectal immunization and rectal boosting with Salmonella typhi Ty 21a vaccine. J Reprod Immunol 52:61–75 [CrossRef]
    [Google Scholar]
  14. Le Guerhier F., Thermet A., Guerret S., Chevallier M., Jamard C., Gibbs C. S., Trepo C., Cova L., Zoulim F. 2003; Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 38:328–334
    [Google Scholar]
  15. Lew D., Parker S. E., Latimer T. 9 other authors 1995; Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 6:553–564 [CrossRef]
    [Google Scholar]
  16. Meseda C. A., Elkins K. L., Merchlinsky M. J., Weir J. P. 2002; Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 186:1065–1073 [CrossRef]
    [Google Scholar]
  17. Miller C. J., McGhee J. R., Gardner M. B. 1993; Mucosal immunity, HIV transmission, and AIDS. Lab Invest 68:129–145
    [Google Scholar]
  18. Nardelli-Haefliger D., Wirthner D., Schiller J. T., Lowy D. R., Hildesheim A., Ponci F., De Grandi P. 2003; Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95:1128–1137 [CrossRef]
    [Google Scholar]
  19. O'Hagan D. T., Singh M. 2003; Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2:269–283 [CrossRef]
    [Google Scholar]
  20. Oka Y., Akbar S. M., Horiike N., Joko K., Onji M. 2001; Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 103:90–97 [CrossRef]
    [Google Scholar]
  21. Okada H., Toguchi H. 1995; Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12:1–99 [CrossRef]
    [Google Scholar]
  22. Polyanskaya N., Bergmeier L. A., Sharpe S. A. 9 other authors 2001; Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody. Virology 279:527–538 [CrossRef]
    [Google Scholar]
  23. Rico M. A., Quiroga J. A., Subira D., Castanon S., Esteban J. M., Pardo M., Carreno V. 2001; Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 33:295–300 [CrossRef]
    [Google Scholar]
  24. Sharpe S., Hanke T., Tinsley-Bown A., Dennis M., Dowall S., McMichael A., Cranage M. 2003; Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313:13–21 [CrossRef]
    [Google Scholar]
  25. Singh M., Vajdy M., Gardner J., Briones M., O'Hagan D. 2001; Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 20:594–602 [CrossRef]
    [Google Scholar]
  26. Singh M., Kazzaz J., Ugozzoli M., Chesko J., O'Hagan D. T. 2004; Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther 4:483–491 [CrossRef]
    [Google Scholar]
  27. Staats H. F., Nichols W. G., Palker T. J. 1996; Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 157:462–472
    [Google Scholar]
  28. Tacket C. O., Roy M. J., Widera G., Swain W. F., Broome S., Edelman R. 1999; Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17:2826–2829 [CrossRef]
    [Google Scholar]
  29. Tinsley-Bown A. M., Fretwell R., Dowsett A. B., Davis S. L., Farrar G. H. 2000; Formulation of poly(d,l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Control Release 66:229–241 [CrossRef]
    [Google Scholar]
  30. Trepo C., Maynard M., Zoulim F. 2003; Perspectives on therapy of hepatitis B. J Hepatol 39 (Suppl. 1):S220–S223 [CrossRef]
    [Google Scholar]
  31. Twaites B. R., de las Heras Alarcon C., Cunliffe D., Lavigne M., Pennadam S., Smith J. R., Gorecki D. C., Alexander C. 2004; Thermo and pH responsive polymers as gene delivery vectors: effect of polymer architecture on DNA complexation in vitro. J Control Release 97:551–566 [CrossRef]
    [Google Scholar]
  32. Wikingsson L., Sjoholm I. 2002; Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 20:3355–3363 [CrossRef]
    [Google Scholar]
  33. Woo P. C., Wong L. P., Zheng B. J., Yuen K. Y. 2001; Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium . Vaccine 19:2945–2954 [CrossRef]
    [Google Scholar]
  34. Zhou F. J., Hu Z. L., Dai J. X., Chen R. W., Shi K., Lin Y., Sun S. H. 2003; Protection of tree shrews by pVAX-PS DNA vaccine against HBV infection. DNA Cell Biol 22:475–478 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80575-0
Loading
/content/journal/jgv/10.1099/vir.0.80575-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error